AI Modeling of Drug Transporter Interactions: A Comprehensive Review for Clinicians

Abstract

Drug transporter proteins are crucial determinants of pharmacokinetics, influencing drug absorption, distribution, and elimination. Recent advancements in artificial intelligence (AI) modeling have transformed the prediction and characterization of drug transporter interactions, offering clinicians and researchers novel insights into drug safety and efficacy. This review synthesizes current scientific evidence and clinical perspectives on AI-driven modeling of drug transporter interactions, emphasizing relevant mechanisms, clinical implications, and emerging guidelines. We discuss the epidemiological burden of transporter-mediated drug interactions, underlying molecular mechanisms, risk factors, diagnostic strategies, management approaches, and the evolving landscape of AI-powered predictive technologies. Practical recommendations for healthcare professionals are outlined, ensuring a thorough understanding of this dynamic and clinically significant field.

Introduction

Drug transporters, including ATP-binding cassette (ABC) and solute carrier (SLC) families, are integral to pharmacokinetic processes, governing the movement of drugs across cellular membranes. Their role in mediating drug-drug interactions (DDIs) has been well established, with transporter modulation affecting therapeutic efficacy and adverse event profiles. Traditional methods for studying transporter interactions are labor-intensive and limited in predictive scope. AI modeling, leveraging machine learning and deep learning algorithms, is rapidly becoming the cornerstone of transporter interaction research by enabling high-throughput, data-driven predictions that inform clinical decision-making. This review aims to provide an in-depth analysis of AI-based approaches to drug transporter interaction modeling, focusing on clinical relevance, mechanistic understanding, and practical applications for healthcare professionals.

Epidemiology / Disease Burden

Transporter-mediated DDIs contribute significantly to adverse drug reactions (ADRs), hospitalizations, and therapeutic failures worldwide. Epidemiological studies estimate that up to 30% of clinically relevant DDIs involve transporter proteins, notably P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), and breast cancer resistance protein (BCRP). Populations at risk include polypharmacy patients, elderly individuals, and those with complex comorbidities. The clinical burden is underscored by increased morbidity, prolonged hospital stays, and heightened healthcare expenditures, necessitating improved predictive and preventive strategies.

Pathophysiology

Drug transporters modulate the pharmacokinetics of substrates by regulating their entry and exit from cells in organs such as the liver, kidney, intestine, and brain. Interactions occur when one drug alters the function of a transporter, affecting the disposition of another substrate drug. Mechanistically, inhibition or induction of transporters can lead to subtherapeutic or toxic drug concentrations, respectively. AI modeling utilizes molecular descriptors, chemical structure-activity relationships, and pharmacogenomic data to predict these complex interactions with greater accuracy than conventional approaches.

Risk Factors

Risk factors for clinically significant drug transporter interactions include genetic polymorphisms in transporter genes, advanced age, hepatic or renal dysfunction, and polypharmacy. Certain drug classes, such as anticoagulants, anticancer agents, and immunosuppressants, are particularly susceptible to transporter-mediated DDIs. Patient-specific factors, including comorbidities and concurrent use of herbal supplements, further compound risk. AI models can integrate patient-specific variables and pharmacogenomic profiles to provide personalized risk assessment, enhancing clinical safety.

Clinical Features

Clinical manifestations of transporter-mediated DDIs are heterogeneous, ranging from therapeutic failure to severe toxicity. Symptoms may include altered drug efficacy, unexpected side effects, or exacerbation of underlying diseases. In oncology, transporter interactions can lead to suboptimal drug delivery to tumor sites, impacting treatment outcomes. In cardiovascular and neurologic diseases, transporter modulation may precipitate arrhythmias, neurotoxicity, or drug accumulation. Recognizing clinical patterns associated with transporter interactions is essential for timely intervention.

Diagnosis

Diagnosing transporter-mediated DDIs involves a combination of clinical assessment, medication history review, therapeutic drug monitoring, and, increasingly, AI-based prediction tools. In silico models trained on large datasets can flag high-risk drug combinations and suggest alternative therapies. Biomarkers, functional assays, and pharmacogenetic testing complement AI predictions, providing a comprehensive diagnostic framework. Integration of AI-driven alerts within electronic health records (EHRs) is enhancing real-time clinical decision support.

Treatment & Management

Management of transporter-mediated DDIs centers on risk mitigation, drug selection, and dose adjustment. AI modeling facilitates individualized therapy by predicting interaction risk and optimizing drug regimens. Strategies include switching to non-interacting alternatives, adjusting dosing intervals, and monitoring for toxicity. Multidisciplinary collaboration among clinicians, pharmacists, and clinical pharmacologists is crucial. Patient education and engagement in therapy decisions further reduce the incidence of adverse outcomes.

Recent Advances / Emerging Therapies

The field has witnessed significant advances in AI modeling, including the use of deep neural networks, ensemble learning, and natural language processing to identify novel transporter substrates and inhibitors. Integration of real-world evidence, multi-omics data, and molecular docking simulations is refining predictive accuracy. Prospective clinical trials are validating AI-generated predictions, paving the way for regulatory acceptance and broader clinical adoption. Emerging therapies include transporter modulators and gene-editing approaches targeting transporter expression, offering new avenues for intervention.

Guideline Recommendations

Recent guidelines from regulatory agencies emphasize the importance of evaluating transporter-mediated interactions during drug development and clinical use. The FDA, EMA, and CPIC recommend incorporating in vitro, in vivo, and in silico assessments, with a growing emphasis on AI modeling for risk stratification. Clinicians are encouraged to utilize validated AI tools integrated within EHRs for real-time DDI screening, especially in high-risk populations. Ongoing guideline updates reflect the dynamic nature of AI-driven research and its expanding clinical utility.

Conclusion

AI modeling is revolutionizing the prediction and management of drug transporter interactions, offering unprecedented precision in identifying clinically significant DDIs. By harnessing large-scale data and advanced algorithms, AI tools are empowering healthcare professionals to optimize pharmacotherapy, minimize adverse events, and advance personalized medicine. Continued collaboration between clinicians, researchers, and regulatory bodies will ensure the safe and effective integration of AI-driven insights into routine clinical practice, ultimately improving patient outcomes in the era of precision therapeutics.